# A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT06630247** · PHASE1 · TERMINATED · sponsor: **Exelixis** · enrollment: 9 (actual)

## Conditions studied

- Solid Cancers
- Solid Tumor Cancer
- Solid Tumor Malignancy
- Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
- Metastatic Solid Tumor
- Locally Advanced Solid Tumor
- Urothelial Cancer of Renal Pelvis

## Interventions

- **DRUG:** XL495
- **DRUG:** ADC cytotoxic agents

## Key facts

- **NCT ID:** NCT06630247
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-17
- **Primary completion:** 2025-05-07
- **Final completion:** 2025-05-07
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630247, "A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06630247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*